BioLight Life Sciences Ltd. announced that, DiagnosTear Ltd. has signed a services agreement with a pharmaceuticals company, pursuant to which DiagnosTear will provide analysis services through its TeaRx multi-parameter diagnostic assays for use in an clinical trial for dry eye syndrome ("DES"). This Agreement marks the first time TeaRx will be used in a drug trial. The TeaRx assays will be used in order to characterize sub populations of responders and non-responders to the new DES drug treatment. Assuming the TeaRx analysis will result with a differentiation between responders and non-responders, the parties will, in good faith, extend their collaboration to a joint-development project of a potential companion diagnostics solution.